Sodium-glucose linked transporter-2 inhibitors: Potential for renoprotection beyond blood glucose lowering?

Kidney International

Volumn 86, Issue 4, 2014, Pages 693-700

  Gilbert, Richard E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

blood pressure; glomerular filtration rate; proximal tubule; sodium glucose linked cotransporter 2; tubuloglomerular feedback; uric acid

Indexed keywords

ALLOPURINOL; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMPAGLIFLOZIN; FIBRONECTIN; GLUCOSE; LOSARTAN; PHLORIZIN; PLACEBO; SCLEROPROTEIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; T 1095; TRANILAST; UNCLASSIFIED DRUG; URIC ACID; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; THIOPHENE DERIVATIVE;

ANTIDIABETIC ACTIVITY; BASOLATERAL MEMBRANE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG POTENCY; GLOMERULUS FILTRATION RATE; GLUCOSE TRANSPORT; HUMAN; HYPERURICEMIA; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY PROXIMAL TUBULE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; URIC ACID BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GLOMERULUS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; GLUCOSE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY GLOMERULUS; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; URIC ACID;

EID: 84908503059     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.451     Document Type: Review

References (76)

1. Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 2013; 33: 984-999.
2. Zhou L, Cryan EV, D'Andrea MR et al. Human cardiomyocytes express high level of Na/glucose cotransporter 1 (SGLT1). J Cell Biochem 2003; 90: 339-346.
3. You G, Lee WS, Barros EJ et al. Molecular characteristics of Na()-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 1995; 270: 29365-29371.
4. Chen J, Williams S, Ho S et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 2010; 1: 57-92.
5. Tazawa S, Yamato T, Fujikura H et al. SLC5A9/SGLT4, a new Nadependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci 2005; 76: 1039-1050.
6. Bakris GL, Fonseca VA, Sharma K et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-1277.
7. Vallon V, Sharma K. Sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Curr Opin Nephrol Hypertens 2010; 19: 425-431.
8. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011; 32: 515-531.
9. Brenner BM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 1983; 23: 647-655.
10. Hayashi K, Epstein M, Loutzenhiser R et al. Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: role of eicosanoid derangements. J Am Soc Nephrol 1992; 2: 1578-1586.
11. Davalos M, Frega NS, Saker B et al. Effect of exogenous and endogenous angiotensin II in the isolated perfused rat kidney. Am J Physiol 1978; 235: F605-F610.
12. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000.
13. Zatz R, Dunn BR, Meyer TW et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
14. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
15. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
16. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
17. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
18. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-693.
19. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
20. Schnermann J, Briggs JP. Tubuloglomerular feedback: mechanistic insights from gene-manipulated mice. Kidney Int 2008; 74: 418-426.
21. Munger KA, Kost CK, Brenner BM et al. The renal circulations and glomerular ultrafiltration. In: Taal MW (ed) Brenner and Rector's The Kidney, 9th edn, vol. 1 (Elsevier: Philadelphia). 2012 pp 94-137.
22. Vallon V, Rose M, Gerasimova M et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013; 304: F156-F167.
23. Thomson SC, Rieg T, Miracle C et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012; 302: R75-R83.
24. Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473.
25. Kohan D, Fioretto P, Tang W et al. Long-term randomized study (104 weeks) of dapagliflozin in patients with type 2 diabetes and moderate renal impairment who have inadequate glycemic control. Kidney Int 2013 (doi:10.1038/ki.2013.356).
26. Coelln-Hough J, Horton E, Meininger G et al. FDA Canagliflozin, Endocrinologic and Metabolic Drugs Advisory Committee Meeting, January 10, 2013. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugs AdvisoryCommittee/UCM336236.pdf (accessed 18 July 2013) 2013 CC1-CC116.
27. Kang DH, Nakagawa T, Feng L et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-2897.
28. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
29. Kanbay M, Sanchez-Lozada LG, Franco M et al. Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant 2011; 26: 430-437.
30. Hovind P, Rossing P, Johnson RJ et al. Serum uric acid as a new player in the development of diabetic nephropathy. J Renal Nutr 2011; 21: 124-127.
31. Ficociello LH, Rosolowsky ET, Niewczas MA et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 2010; 33: 1337-1343.
32. Hovind P, Rossing P, Tarnow L et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. Diabetes 2009; 58: 1668-1671.
33. Maahs DM, Caramori L, Cherney DZ et al. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep 2013; 13: 550-559.
34. Miao Y, Ottenbros SA, Laverman GD et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 2011; 58: 2-7.
35. Soma J, Sato K, Saito H et al. Effect of tranilast in early-stage diabetic nephropathy. Nephrol Dial Transplant 2006; 21: 2795-2799.
36. Soma J, Sugawara T, Huang YD et al. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 2002; 92: 693-698.
37. Crittenden DBK, Han Na, Fisher MC et al. New and emerging therapies for gout. Clin Investig 2011; 1: 1563-1575.
38. Levinson DJ, Sorensen LB. Renal handling of uric acid in normal and gouty subject: evidence for a 4-component system. Ann Rheum Dis 1980; 39: 173-179.
39. Marangella M. Uric acid elimination in the urine. Pathophysiological implications. Contrib Nephrol 2005; 147: 132-148.
40. Whitehead TP, Jungner I, Robinson D et al. Serum urate, serum glucose and diabetes. Ann Clin Biochem 1992; 29(Pt 2): 159-161.
41. Cook DG, Shaper AG, Thelle DS et al. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgraduate Med J 1986; 62: 1001-1006.
42. Skeith MD, Healey LA, Cutler RE. Urate excretion during mannitol and glucose diuresis. J Lab Clin Med 1967; 70: 213-220.
43. Quinones-Galvan A, Ferrannini E. Renal effects of insulin in man. J Nephrol 1997; 10: 188-191.
44. Skeith MD, Healey LA, Cutler RE. Effect of phloridzin on uric acid excretion in man. Am J Physiol 1970; 219: 1080-1082.
45. Musso G, Gambino R, Cassader M et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375-393.
46. Agency EM. Forxiga Product Information. http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/ 002322/WC500136026.pdf (accessed 18 July 2013) 2012.
47. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis 2012; 19: 358-371.
48. Witkowska K, Smith KM, Yao SY et al. Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses. Am J Physiol Renal Physiol 2012; 303: F527-F539.
49. Cheeseman C. Solute carrier family 2, member 9 and uric acid homeostasis. Curr Opin Nephrol Hypertens 2009; 18: 428-432.
50. List JF, Woo V, Morales E et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-657.
51. Wilding JP, Norwood P, T'Joen C et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656-1662.
52. Squibb B-M. FDA Briefing Document NDA 202293 Dapagliflozin Tablets, 5 and 10 mg Advisory Committee Meeting July 19, 2011. http://www. fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ ucm262994.pdf (accessed 18 July 2013) 2011.
53. Taler SJ, Agarwal R, Bakris GL et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis 2013; 62: 201-213.
54. Fernandez Juarez G, Luno J, Barrio V et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis 2013; 61: 211-218.
55. Leiter LA, Berard L, Bowering CK et al. Type 2 diabetes,ellitis management in Canada: is it improving? Can J Diabetes 2013; 37: 82-89.
56. Bader R, Bader E, Grung KE et al. Structure and function of the kidney in diabetic glomerulosclerosis: correlations between morphological and functional parametes. Pathol Res Pract 1980; 167: 204-216.
57. Bohle A, Wehrmann M, Bogenschutz O et al. The pathogenesis of chronic renal failure in diabetic nephropathy: investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991; 187: 251-259.
58. Cordonnier DJ, Pinel N, Barro C et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. J Am Soc Nephrol 1999; 10: 1253-1263.
59. Taft J, Nolan CJ, Yeung SP et al. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43: 1046-1051.
60. Zhang SL, Filep JG, Hohman TC et al. Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int 1999; 55: 454-464.
61. Rocco MV, Chen Y, Goldfarb S et al. Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule. Kidney Int 1992; 41: 107-114.
62. Ziyadeh FN, Snipes ER, Watanabe M et al. High glucose induces cell hypertrophy and stimulates collagen gene transcription in proximal tubule. Am J Physiol 1990; 259: F704-F714.
63. Gilbert RE, Wilkinson-Berka JL, Johnson DW et al. Renal expression of transforming growth factor-beta inducible gene-h3 (beta ig-h3) in normal and diabetic rats. Kidney Int 1998; 54: 1052-1062.
64. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999; 56: 1627-1637.
65. Morrisey K, Steadman R, Williams JD et al. Renal proximal tubular cell fibronectin accumulation in response to glucose is polyol pathway dependent. Kidney Int 1999; 55: 160-167.
66. Panchapakesan U, Pegg K, Gross S et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 2013; 8: e54442.
67. Grempler R, Thomas L, Eckhardt M et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83-90.
68. O'Brien RC, Cooper ME, Jerums G et al. The effects of perindopril and triple therapy in a normotensive model of diabetic nephropathy. Diabetes 1993; 42: 604-609.
69. Malatiali S, Francis I, Barac-Nieto M. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res 2008; 2008: 305403.
70. Arakawa K, Ishihara T, Oku A et al. Improved diabetic syndrome in C57BL/ KsJ-db/db mice by oral administration of the Na()-glucose cotransporter inhibitor T-1095. Br J Pharmacol 2001; 132: 578-586.
71. Vallon V. Tubuloglomerular feedback and the control of glomerular filtration rate. News Physiological Sci 2003; 18: 169-174.
72. Kanbay M, Huddam B, Azak A et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011; 6: 1887-1894.
73. Kanbay M, Ozkara A, Selcoki Y et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39: 1227-1233.
74. Siu YP, Leung KT, Tong MK et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59.
75. Goicoechea M, de Vinuesa SG, Verdalles U et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388-1393.
76. Momeni A, Shahidi S, Seirafian S et al. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iranian J Kidney Dis 2010; 4: 128-132.